146 related articles for article (PubMed ID: 30806569)
41. Treatment experience, burden, and unmet needs (TRIBUNE) in multiple sclerosis: the costs and utilities of MS patients in Canada.
Karampampa K; Gustavsson A; Miltenburger C; Kindundu CM; Selchen DH
J Popul Ther Clin Pharmacol; 2012; 19(1):e11-25. PubMed ID: 22247419
[TBL] [Abstract][Full Text] [Related]
42. Cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing forms of multiple sclerosis in the United States.
Mauskopf J; Fay M; Iyer R; Sarda S; Livingston T
J Med Econ; 2016; 19(4):432-42. PubMed ID: 26707273
[TBL] [Abstract][Full Text] [Related]
43. Cost-effectiveness analysis of computerized tomography in the routine follow-up of patients after primary treatment for Hodgkin's disease.
Guadagnolo BA; Punglia RS; Kuntz KM; Mauch PM; Ng AK
J Clin Oncol; 2006 Sep; 24(25):4116-22. PubMed ID: 16943528
[TBL] [Abstract][Full Text] [Related]
44. Assessing the cost-effectiveness of treating chronic hepatitis C virus in people who inject drugs in Australia.
Visconti AJ; Doyle JS; Weir A; Shiell AM; Hellard ME
J Gastroenterol Hepatol; 2013 Apr; 28(4):707-16. PubMed ID: 23173753
[TBL] [Abstract][Full Text] [Related]
45. The Economic Impact of Acetabular Labral Tears: A Cost-effectiveness Analysis Comparing Hip Arthroscopic Surgery and Structured Rehabilitation Alone in Patients Without Osteoarthritis.
Lodhia P; Gui C; Chandrasekaran S; Suarez-Ahedo C; Dirschl DR; Domb BG
Am J Sports Med; 2016 Jul; 44(7):1771-80. PubMed ID: 27190068
[TBL] [Abstract][Full Text] [Related]
46. Cost effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US.
Parthan A; Kruse M; Yurgin N; Huang J; Viswanathan HN; Taylor D
Appl Health Econ Health Policy; 2013 Oct; 11(5):485-97. PubMed ID: 23868102
[TBL] [Abstract][Full Text] [Related]
47. Newborn screening by tandem mass spectrometry for medium-chain Acyl-CoA dehydrogenase deficiency: a cost-effectiveness analysis.
Venditti LN; Venditti CP; Berry GT; Kaplan PB; Kaye EM; Glick H; Stanley CA
Pediatrics; 2003 Nov; 112(5):1005-15. PubMed ID: 14595039
[TBL] [Abstract][Full Text] [Related]
48. Estimated health benefits, costs, and cost-effectiveness of eliminating industrial trans-fatty acids in Australia: A modelling study.
Marklund M; Zheng M; Veerman JL; Wu JHY
PLoS Med; 2020 Nov; 17(11):e1003407. PubMed ID: 33137090
[TBL] [Abstract][Full Text] [Related]
49. Cost-effectiveness analysis of entecavir versus lamivudine in the first-line treatment of Australian patients with chronic hepatitis B.
Arnold E; Yuan Y; Iloeje U; Cook G
Appl Health Econ Health Policy; 2008; 6(4):231-46. PubMed ID: 19382822
[TBL] [Abstract][Full Text] [Related]
50. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population.
Salomon JA; Weinstein MC; Hammitt JK; Goldie SJ
JAMA; 2003 Jul; 290(2):228-37. PubMed ID: 12851278
[TBL] [Abstract][Full Text] [Related]
51. The costs, clinical benefits, and cost-effectiveness of screening for cervical cancer in HIV-infected women.
Goldie SJ; Weinstein MC; Kuntz KM; Freedberg KA
Ann Intern Med; 1999 Jan; 130(2):97-107. PubMed ID: 10068381
[TBL] [Abstract][Full Text] [Related]
52. Frontline rituximab monotherapy induction versus a watch and wait approach for asymptomatic advanced-stage follicular lymphoma: A cost-effectiveness analysis.
Prica A; Chan K; Cheung M
Cancer; 2015 Aug; 121(15):2637-45. PubMed ID: 25877511
[TBL] [Abstract][Full Text] [Related]
53. Cost-Effectiveness of Total Hip Arthroplasty Versus Nonoperative Management in Normal, Overweight, Obese, Severely Obese, Morbidly Obese, and Super Obese Patients: A Markov Model.
Ponnusamy KE; Vasarhelyi EM; McCalden RW; Somerville LE; Marsh JD
J Arthroplasty; 2018 Dec; 33(12):3629-3636. PubMed ID: 30266324
[TBL] [Abstract][Full Text] [Related]
54. The long-term cost of multiple sclerosis in France and potential changes with disease-modifying interventions.
Kobelt G; Texier-Richard B; Lindgren P
Mult Scler; 2009 Jun; 15(6):741-51. PubMed ID: 19383645
[TBL] [Abstract][Full Text] [Related]
55. Cost effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a lifetime model.
Millar JA; Millward MJ
Pharmacoeconomics; 2007; 25(5):429-42. PubMed ID: 17488140
[TBL] [Abstract][Full Text] [Related]
56. A Cost-Effectiveness Analysis of Nivolumab Compared with Ipilimumab for the Treatment of BRAF Wild-Type Advanced Melanoma in Australia.
Bohensky MA; Pasupathi K; Gorelik A; Kim H; Harrison JP; Liew D
Value Health; 2016 Dec; 19(8):1009-1015. PubMed ID: 27987627
[TBL] [Abstract][Full Text] [Related]
57. The impact of multiple sclerosis severity on health state utility values: Evidence from Australia.
Ahmad H; Taylor BV; van der Mei I; Colman S; O'Leary BA; Breslin M; Palmer AJ
Mult Scler; 2017 Jul; 23(8):1157-1166. PubMed ID: 27698247
[TBL] [Abstract][Full Text] [Related]
58. Understanding the costs of care for cystic fibrosis: an analysis by age and health state.
van Gool K; Norman R; Delatycki MB; Hall J; Massie J
Value Health; 2013; 16(2):345-55. PubMed ID: 23538187
[TBL] [Abstract][Full Text] [Related]
59. Cost-effectiveness of cladribine tablets versus fingolimod in patients with highly active relapsing multiple sclerosis in Portugal.
Pinheiro B; Guerreiro R; Costa J; Miguel LS
J Med Econ; 2020 May; 23(5):484-491. PubMed ID: 31951777
[No Abstract] [Full Text] [Related]
60. The Cost-Effectiveness of Dual Mobility Implants for Primary Total Hip Arthroplasty: A Computer-Based Cost-Utility Model.
Barlow BT; McLawhorn AS; Westrich GH
J Bone Joint Surg Am; 2017 May; 99(9):768-777. PubMed ID: 28463921
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
